Olivier Garraud1,2*- 1EA3064, University of Lyon Saint-Etienne, Saint-Etienne, France
- 2Institut National de la Transfusion Sanguine (INTS), Paris, France
Blood platelets are essential for the earliest stages of coagulation, namely, primary hemostasis. They adhere to damaged vessel endothelium, stick to each other (aggregate), and form clots; this prevents bleeding. For most physicians, those attributes of platelets are exactly what they learned in medical school years ago, and this basic knowledge seems quite enough to allow a valid therapeutic strategy when numbers or hemostatic functions of platelets are aberrant. In some cases, this consists in prescribing anti-platelet drugs (aspirin or more sophisticated drugs) to prevent overly active clotting in cardiovascular and metabolic dysfunctions. In other instances, this consists in prescribing platelet transfusions when the platelet count is dangerously low (or – in exceptional occasions – when platelets are dysfunctional). It could be as simple as that, but in fact, it is often not, because platelets are more versatile than initially thought (or expected) and some modification is needed in many cases (1). To cite only one example, anti-viral treatment of HIV infection causes atheroma and platelet deposition, emphasizing the recently recognized inflammatory function of platelets (2, 3); anti-platelet therapy seems a likely approach, but this is not current practice yet.
Thus, let us imagine that a scientific magazine writer decides to contribute a paper emphasizing novel advances in platelet research; the journal’s instructions are: no more than four key points, a concise style, and only issues that can be understood by a large community; and – icing on the cake – a translation into today’s or tomorrow’s therapeutics. What would he/she insist on?
The proposed four points, which in our opinion, are either really new or newly rediscovered (after having been buried for decades and perhaps completely forgotten) would be:
– Not only are platelets genuine cells but also are they intelligent cells, as they can sense dangers differentially (4, 5).
– Despite platelets have been suspected to be inflammatory cells as soon as in the early 70s’, this opinion either has been ignored or faded (6). Platelets indeed participate in innate immunity and they can influence adaptive immunity (7–9); they are “licensed” as highly potent pro-inflammatory cells (10).
– Platelets have a remarkable ability to sense and bind microbial agents, in particular, pathogenic viruses, and foremost bacteria (11, 12); interestingly enough, this property has been recognized in the early 70s’ (13) but not exploited since recently (14).
– Platelets have more than one cell partner (the endothelial cell) as they intimately interact with the leukocyte, not only at different phases of the clot formation but also in tissue pathology (15, 16); this is also an issue, which is rediscovered after having been under-acknowledged according to its importance (17).
Why are all four key points really interesting for the medical community, and – beyond – to the patient community?
Concisely, we suggest three reasons:
– First, these findings lead to revisiting the essential functions of platelets. While platelets were principally considered relevant to vascular pathology (vessel injury and bleeding), today they are also considered as sentinels along the vascular tree, detecting insults and making daily repairs. Importantly, platelets perform an immune function as danger sensors, detecting circulating viruses and bacteria.
– Second, because they are non-nucleated, and mere fragments of the megakaryocyte, platelets were thought to be terminally differentiated cells, limited in function, fully equipped with static content; only one option remained to enrich their functions: to borrow glycoproteins from the environment. Recent evidence is that platelets can give rise to progeny platelets (18). Do these daughter cells possess identical capabilities to those of the mother cell? And are there no distinct subsets of platelets with different functions in vivo, as might be indicated by varying capacity for differential cytokine/chemokine secretion? Further, platelets are capable of using RNA to make secreted proteins (19, 20), an issue, which was suspected as in the late 60s’ (21) and then disregarded (it is not fully consensual yet): not so a static dead-end cell after all!
– Lastly, platelets have been considered for some time as sentinels in severe clinical infection and particularly in sepsis (14). Maybe platelets are not just sentinels, but one among the primary targets of infectious pathogens, contributing to severe organ failure, especially because of their intimate relationship with leukocytes (22). Platelets were recently shown to infiltrate joints and cause serious inflammatory damage. Collectively, these observations call for revisiting at least partly the therapy of certain auto-inflammatory and infectious disease: what about anti-platelet drug use? Oh yes, some are very cheap such as aspirin: but is this effective and safe? In all, anti-platelet therapy reveals itself far more complex and nuanced than previously considered (23).
In aggregate, platelets span the classic field of hemostasis and thrombosis and the novel field of immunology and inflammation. Even transfusion medicine gurus are confused. Most were taught that low platelet counts below a given threshold (ranging from 10,000 to 30,000/μL of blood) require a platelet transfusion; now, they are kindly advised that all platelet transfusions are not equal and some transfusions may well be more pro-inflammatory than others (24, 25). How can they choose? They cannot, because the blood bank has made the choice for them: they are left with some confusion and concerns for their patients. Of note, this last paragraph would certainly not have been appropriate for the hypothetical science writer, because it does not speak to current reality of medical practice. Well, maybe not yet; but physicians and scientists are making significant progress in rendering platelet transfusion definitely much safer in terms of reduction of immunological hazards, and detecting genetic predisposition to harm (26, 27). Thus, we have the new general understanding that platelets are not that simple, after all, and that there may well be much more to learn again.
Conflict of Interest Statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
The author wishes to thank Dr. Neil Blumberg, University of Rochester, NY, USA, for sharing thoughts and for having given kind advice on this Editorial.
References
1. Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, et al. Platelet Transfusion Guidelines Panel transfusion: a systematic review of the clinical evidence. Transfusion (2015) 55(5):1116–27. doi: 10.1111/trf.12943
2. Nording HM, Seizer P, Langer HF. Platelets in inflammation and atherogenesis. Front Immunol (2015) 6:98. doi:10.3389/fimmu.2015.00098
3. Damien P, Cognasse F, Lucht F, Suy F, Pozzetto B, Garraud O, et al. Highly active antiretroviral therapy alters inflammation linked to platelet cytokines in HIV-1-infected patients. J Infect Dis (2013) 208:868–70. doi:10.1093/infdis/jit260
4. Garraud O, Cognasse F. Are platelets cells? And if yes, are they immune cells? Front Immunol (2015) 6:70. doi:10.3389/fimmu.2015.0007
5. Rondina MT, Garraud O. Emerging evidence for platelets as immune and inflammatory effector cells. Front Immunol (2014) 5:653. doi:10.3389/fimmu.2014.00653
6. Nachman RL, Weksler B. The platelet as an inflammatory cell. Ann N Y Acad Sci (1972) 201:131–7. doi:10.1111/j.1749-6632.1972.tb16294.x
7. Yeaman MR. Platelets: at the nexus of antimicrobial defence. Nat Rev Microbiol (2014) 12:426–37. doi:10.1038/nrmicro3269
8. Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood (2014) 123:2759–67. doi:10.1182/blood-2013-11-462432
9. Cognasse F, Nguyen KA, Damien P, McNicol A, Pozzetto B, Hamzeh-Cognasse H, et al. The Inflammatory role of platelets via their TLRs and Siglec receptors. Front Immunol (2015) 6:83. doi:10.3389/fimmu.2015.00083
10. Semple JW, Italiano JE Jr., Freedman J. Platelets and the immune continuum. Nat Rev Immunol (2011) 11:264–74. doi:10.1038/nri2956
11. Hamzeh-Cognasse H, Damien P, Chabert A, Pozzetto B, Cognasse F, Garraud O. Platelets and infections – complex interactions with bacteria. Front Immunol (2015) 6:82. doi:10.3389/fimmu.2015.00082
12. Assinger A. Platelets and infection – an emerging role of platelets in viral infection. Front Immunol (2014) 5:649. doi:10.3389/fimmu.2014.00649
13. Clawson CC, White JG. Platelet interaction with bacteria. II. Fate of the bacteria. Am J Pathol (1971) 65:381–97.
14. Franks Z, Carlisle M, Rondina MT. Current challenges in understanding immune cell functions during septic syndromes. BMC Immunol (2015) 16:11. doi:10.1186/s12865-015-0073-4
15. Gros A, Ollivier V, Ho-Tin-Noé B. Platelets in inflammation: regulation of leukocyte activities and vascular repair. Front Immunol (2015) 5:678. doi:10.3389/fimmu.2014.00678
16. Goldenberg NM, Kuebler W. Endothelial cell regulation of pulmonary vascular tone, inflammation, and coagulation. Compr Physiol (2015) 5:531–59. doi:10.1002/cphy.c140024
17. Hobbs JB, Cliff WJ. A study of allograft kidney rejection occurring simultaneously in whole organ and ear chamber grafts in the rabbit. J Exp Med (1973) 137:776–98. doi:10.1084/jem.137.3.776
18. Schwertz H, Köster S, Kahr WH, Michetti N, Kraemer BF, Weitz DA, et al. Anucleate platelets generate progeny. Blood (2010) 115:3801–9. doi:10.1182/blood-2009-08-239558
19. Lannan KL, Sahler J, Kim N, Spinelli SL, Maggirwar SB, Garraud O, et al. Breaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticles. Front Immunol (2015) 6:48. doi:10.3389/fimmu.2015.00048
20. Schubert S, Weyrich AS, Rowley JW. A tour through the transcriptional landscape of platelets. Blood (2014) 124:493–502. doi:10.1182/blood-2014-04-512756
21. Warshaw AL, Laster L, Shulman NR. Protein synthesis by human platelets. J Biol Chem (1967) 242:2094–7.
22. Rossaint J, Zarbock A. Platelets in leucocyte recruitment and function. Cardiovasc Res (2015). doi:10.1093/cvr/cvv048
23. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost (2008) 99:466–72. doi:10.1160/TH07-11-0673
24. Katus MC, Szczepiorkowski ZM, Dumont LJ, Dunbar NM. Safety of platelet transfusion: past, present and future. Vox Sang (2014) 107:103–13. doi:10.1111/vox.12146
25. Stolla M, Refaai MA, Heal JM, Spinelli SL, Garraud O, Phipps RP, et al. Platelet transfusion – the new immunology of an old therapy. Front Immunol (2015) 6:28. doi:10.3389/fimmu.2015.00028
26. Garraud O, Cognasse F, Hamzeh-Cognasse H, Spinelli S, Phipps RP, Blumberg N. Removal of biologic response modifiers associated with platelet transfusion reactions: strategies worth considering? Transfusion (2014) 54:2583. doi:10.1111/trf.12811
Keywords: platelets, inflammation, infection, transfusion, immunity
Citation: Garraud O (2015) Editorial: Platelets as immune cells in physiology and immunopathology. Front. Immunol. 6:274. doi: 10.3389/fimmu.2015.00274
Received: 04 May 2015; Accepted: 18 May 2015;
Published: 03 June 2015
Edited by:
Pietro Ghezzi, Brighton and Sussex Medical School, UKReviewed by:
Rolando Rumbaut, Baylor College of Medicine, USACopyright: © 2015 Garraud. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Olivier Garraud, ogarraud@ints.fr